Programme in Physiology and Experimental Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Br J Pharmacol. 2009 Oct;158(4):972-81. doi: 10.1111/j.1476-5381.2009.00168.x. Epub 2009 Apr 30.
The hepoxilin pathway was discovered over two decades ago. Products in this pathway are derived through the 12S-lipoxygenase/hepoxilin synthase enzyme system and contain intrinsic biological activity. This activity relates to the reorganization of calcium and potassium ions within the cell, and in inflammation and insulin secretion. Although the natural hepoxilins are chemically unstable, chemical analogues (PBTs) have been synthesized with chemical and biological stability. The PBTs antagonize the natural hepoxilins. The PBTs showed bioavailability, excellent tolerance and stability in vivo. In proof of principle studies in vivo in animal models, the PBTs have shown actions as anti-inflammatory agents, anti-thrombotic agents, anti-cancer agents and anti-diabetic agents. These studies demonstrate the effectiveness of the base structure of the hepoxilin (and PBT) molecule and serve as an excellent framework for the design and preparation of second-generation compounds with improved pharmaceutical properties as therapeutics for the above-mentioned diseases.
海泼林途径是二十多年前发现的。该途径的产物是通过 12S-脂氧合酶/海泼林合酶酶系统产生的,具有内在的生物学活性。这种活性与细胞内钙离子和钾离子的重排有关,与炎症和胰岛素分泌有关。尽管天然海泼林的化学性质不稳定,但已经合成了具有化学和生物学稳定性的化学类似物(PBT)。PBT 拮抗天然海泼林。PBT 在体内具有生物利用度、良好的耐受性和稳定性。在动物模型的体内原理验证研究中,PBT 表现出抗炎、抗血栓、抗癌和抗糖尿病作用。这些研究证明了海泼林(和 PBT)分子的基本结构的有效性,并为设计和制备具有改善的药物性质的第二代化合物提供了极好的框架,作为上述疾病的治疗方法。